title: [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
abstract: OBJECTIVE
  There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate.
  
  
  METHODS
  Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle.
  
  
  RESULTS
  Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26%) demonstrated a partial objective response (PR), and ten (37%) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR + ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41%). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36% and 24%, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96%), leukocytopenia (89%), anorexia (81%), alopecia (67%), thrombocytopenia (44%), hematuria (38%), renal dysfunction (19%) and liver dysfunction (7%) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock.
  
  
  CONCLUSIONS
  We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.
authors.affiliation: Department of Urology, Okayama University Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Maki
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: Y
authors.initials: Y
authors.lastname: Nasu
authors.forename: H
authors.initials: H
authors.lastname: Kumon
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
authors.forename: T
authors.initials: T
authors.lastname: Tanahashi
authors.forename: K
authors.initials: K
authors.lastname: Nanba
authors.forename: T
authors.initials: T
authors.lastname: Ohashi
authors.forename: K
authors.initials: K
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Saika
authors.forename: T
authors.initials: T
authors.lastname: Asahi
authors.forename: M
authors.initials: M
authors.lastname: Saegusa
authors.forename: Y
authors.initials: Y
authors.lastname: Ozaki
authors.forename: Y
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Katayama
authors.forename: M
authors.initials: M
authors.lastname: Kobuke
authors.forename: S
authors.initials: S
authors.lastname: Uno
authors.forename: J
authors.initials: J
authors.lastname: Ochi
authors.forename: K
authors.initials: K
authors.lastname: Kobashi
authors.forename: K
authors.initials: K
authors.lastname: Hata
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D009325:Nausea / Q000139:chemically induced; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014839:Vomiting / Q000139:chemically induced
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002945:Cisplatin; D007069:Ifosfamide